The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2026
Pediatric lung transplantation in Japan across legislative and allocation reforms: A nationwide registry analysis of waitlist and post-transplant outcomes.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hirama Takashi, Omiya Kaori, Oishi Hisashi, Chida Masayuki, Sato Masaaki, Chen-Yoshikawa Toyofumi, Hoshikawa Yasushi, Nakajima Daisuke, Shintani Yasushi, Toyooka Shinichi, Shiraishi Takeshi, Matsumoto Keitaro, Okada Yoshinori
Аннотация
BACKGROUND: Pediatric lung transplantation is a life-saving option for end-stage lung disease, but national data from Japan, particularly regarding the impact of recent policy changes, are limited.
METHODS: Nationwide registries of candidates (deceased-donor waitlist) and recipients in Japan (1998-2024) were analyzed with follow-up through July 2025. Outcomes were evaluated across three eras defined by the 2010 legislative revision and the 2020 pediatric priority rules. Waitlist outcomes were assessed within 2 years of listing and post-transplant survival within 2 years of transplantation (administrative censoring at 730 days) to support fair era comparisons.
RESULTS: Among 2732 candidates, 149 (5.5%) were children. Within 2 years of listing, pediatric candidates were more likely to undergo lung transplantation than adults (35.6% vs 18.2%) and less likely to die on the waitlist (13.4% vs 29.7%). The proportion transplanted within 2 years increased from 9.4% in 1998-2009 to 38.2% in 2010-2019 and 49.0% in 2020-2024, while 2-year waitlist death decreased from 21.9% to 13.2% and 8.2%. At 2 years after transplantation, survival was 86.0% in pediatric recipients and 81.8% in adults; pediatric recipient status remained independently associated with lower mortality (aHR 0.47, 95% CI 0.32-0.71; p < 0.001). Descriptive Kaplan-Meier curves up to 10 years suggested favorable longer-term survival, with broadly comparable outcomes after pediatric living-donor and deceased-donor transplantation.
CONCLUSIONS: Pediatric lung transplantation in Japan remains numerically limited but has substantially benefited from legislative and allocation reforms, with improved access to transplantation and reduced waitlist mortality. These findings provide a current national reference for pediatric lung transplantation in a donor-limited setting.
METHODS: Nationwide registries of candidates (deceased-donor waitlist) and recipients in Japan (1998-2024) were analyzed with follow-up through July 2025. Outcomes were evaluated across three eras defined by the 2010 legislative revision and the 2020 pediatric priority rules. Waitlist outcomes were assessed within 2 years of listing and post-transplant survival within 2 years of transplantation (administrative censoring at 730 days) to support fair era comparisons.
RESULTS: Among 2732 candidates, 149 (5.5%) were children. Within 2 years of listing, pediatric candidates were more likely to undergo lung transplantation than adults (35.6% vs 18.2%) and less likely to die on the waitlist (13.4% vs 29.7%). The proportion transplanted within 2 years increased from 9.4% in 1998-2009 to 38.2% in 2010-2019 and 49.0% in 2020-2024, while 2-year waitlist death decreased from 21.9% to 13.2% and 8.2%. At 2 years after transplantation, survival was 86.0% in pediatric recipients and 81.8% in adults; pediatric recipient status remained independently associated with lower mortality (aHR 0.47, 95% CI 0.32-0.71; p < 0.001). Descriptive Kaplan-Meier curves up to 10 years suggested favorable longer-term survival, with broadly comparable outcomes after pediatric living-donor and deceased-donor transplantation.
CONCLUSIONS: Pediatric lung transplantation in Japan remains numerically limited but has substantially benefited from legislative and allocation reforms, with improved access to transplantation and reduced waitlist mortality. These findings provide a current national reference for pediatric lung transplantation in a donor-limited setting.